Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP Highlights: No For Xyndari, Edaravone MAA Pulled And Good News For Univar’s Cufence

Executive Summary

This month’s meeting of the European Medicines Agency’s CHMP appears to have been eventful. One marketing authorization application was rejected, one was pulled, and an earlier negative opinion was upheld. Four MAAs were recommended for approval, including a new treatment from Univar for Wilson’s disease.

Advertisement

Related Content

EU Ruling Raises New Questions For Orphan Designation
European CHMP Opinions and MAA Updates
Emmaus and Mitsubishi Tanabe Refuse To Take EU Approval Blows Quietly
Companies Keep The Faith As New Products Await EMA Verdict

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125378

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel